share_log

Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target

Moomoo 24/7 ·  Apr 10 09:33

Cantor Fitzgerald analyst Charles Duncan reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and maintains $37 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment